Janux Therapeutics Inc (JANX)
48.21
-1.57
(-3.15%)
USD |
NASDAQ |
Apr 24, 16:00
48.13
-0.08
(-0.17%)
After-Hours: 20:00
Janux Therapeutics Cash from Investing (TTM): -41.19M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -41.19M |
| September 30, 2023 | -53.92M |
| June 30, 2023 | 27.29M |
| March 31, 2023 | 18.46M |
| December 31, 2022 | 58.27M |
| September 30, 2022 | 67.20M |
| June 30, 2022 | -158.11M |
| Date | Value |
|---|---|
| March 31, 2022 | -309.74M |
| December 31, 2021 | -340.96M |
| September 30, 2021 | -348.29M |
| June 30, 2021 | -142.75M |
| March 31, 2021 | -0.153M |
| December 31, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-348.29M
Minimum
Sep 2021
67.20M
Maximum
Sep 2022
-94.15M
Average
-41.19M
Median
Dec 2023
Cash from Investing (TTM) Benchmarks
| Viking Therapeutics Inc | -179.09M |
| Equillium Inc | -4.762M |
| Minerva Neurosciences Inc | 0.00 |
| Arvinas Inc | 203.50M |
| Calidi Biotherapeutics Inc | -- |